Their study was focused on grade 4 gliomas; our study expanded this finding to other grades of gliomas, albeit with a modification: the third immune marker that may appropriately define this population is TIGIT, since we found that TIM-3 was not significantly expressed on T cells. Here, HAVCR2 is linked to central nervous system cancer.